Pfizer Exits Early Neuroscience, But M&A Could Allow Later Re-Entry
Executive Summary
Pfizer is abandoning research to find new drugs for Alzheimer’s and Parkinson’s disease, realizing that finding treatments for the diseases is very tough - but M&A could allow an eventual return, analysts say.
You may also be interested in...
Cerevel Goes Public In SPAC Merger To Fund Neuroscience Programs
Deal Snapshot: The $445m Cerevel gains will help as it plans to have at least six programs in the clinic within the next year. CEO Tony Coles will head up a public firm for the first time since Amgen bought Onyx.
Cerevel Puts Tavapadon Into Phase III for Parkinson’s
The company, launched in October 2018 with neuroscience programs spun out from Pfizer and supported by $350m from Bain, believes it has a treatment that could prove effective across the full spectrum of Parkinson’s disease.
Pfizer, Lilly Weigh In On Dosing And Safety Of Non-Opioid Pain Drug Tanezumab
Two dosing regimens hit the mark on three co-primary endpoints and the rate of rapidly progressive osteoarthritis was low at 1.3% in a Phase III study of the NGF inhibitor presented on Oct. 23.
Need a specific report? 1000+ reports available Buy Reports